SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-060156
Filing Date
2024-07-09
Accepted
2024-07-09 17:01:28
Documents
15
Period of Report
2024-07-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0209134-8k425_arcabio.htm   iXBRL 8-K 34286
2 FORM OF AMENDMENT ea020913401ex10-1_arcabio.htm EX-10.1 11118
3 FORM OF A&R SUBSCRIPTION AGREEMENT ea020913401ex10-2_arcabio.htm EX-10.2 148948
  Complete submission text file 0001213900-24-060156.txt   408613

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE abio-20240703.xsd EX-101.SCH 3012
5 XBRL LABEL FILE abio-20240703_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE abio-20240703_pre.xml EX-101.PRE 22357
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0209134-8k425_arcabio_htm.xml XML 3677
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 241107999
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)